422 related articles for article (PubMed ID: 24238791)
41. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study.
Lee SJ; Yim HJ; Hwang SG; Seo YS; Kim JH; Yoon EL; Lee JM; Kim BH; Park SJ; Park YM; Kim HS; Lee SH; Ahn SH; Lee JI; Lee JW; Kim IH; Kim HS; Hong SP
Scand J Gastroenterol; 2013 Feb; 48(2):196-204. PubMed ID: 23194375
[TBL] [Abstract][Full Text] [Related]
42. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.
Yim HJ; Seo YS; Yoon EL; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
Liver Int; 2013 Feb; 33(2):244-54. PubMed ID: 23295056
[TBL] [Abstract][Full Text] [Related]
43. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
[TBL] [Abstract][Full Text] [Related]
44. [Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir].
Li M; Wu J; Xu G; Zhang Q; Chen Z; Liu Z
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1823-6. PubMed ID: 24369254
[TBL] [Abstract][Full Text] [Related]
45. Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.
Cho EY; Yim HJ; Jung YK; Suh SJ; Seo YS; Kim JH; Kim HS; Lee SH; Ahn SH; Lee JI; Jeong SH; Kim JW; Lee JW; Kim IH; Kim HS; Park SJ; Lee JM; Hwang SG;
Gut Liver; 2017 Jan; 11(1):129-135. PubMed ID: 27538443
[TBL] [Abstract][Full Text] [Related]
46. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.
Chen EQ; Wang LC; Lei J; Xu L; Tang H
Virol J; 2009 Oct; 6():163. PubMed ID: 19818142
[TBL] [Abstract][Full Text] [Related]
48. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
49. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
[TBL] [Abstract][Full Text] [Related]
50. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.
Lee YB; Lee JH; Choi WM; Cho YY; Yoo JJ; Lee M; Lee DH; Cho Y; Yu SJ; Kim YJ; Yoon JH; Kim CY; Lee HS
Antimicrob Agents Chemother; 2013 Dec; 57(12):6325-32. PubMed ID: 24100506
[TBL] [Abstract][Full Text] [Related]
52. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
[TBL] [Abstract][Full Text] [Related]
53. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
Lee JH; Yoon JH; Cho EJ; Yang HJ; Jang ES; Kwak MS; Hwang SY; Yu SJ; Lee CH; Kim YJ; Kim CY; Lee HS
J Clin Gastroenterol; 2012 Mar; 46(3):243-50. PubMed ID: 21716122
[TBL] [Abstract][Full Text] [Related]
54. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
55. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
[TBL] [Abstract][Full Text] [Related]
56. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
[TBL] [Abstract][Full Text] [Related]
57. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
58. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
[TBL] [Abstract][Full Text] [Related]
59. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Dakin H; Fidler C; Harper C
Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
[TBL] [Abstract][Full Text] [Related]
60. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]